OpGen Stock Forecast, Price & News

OpGen (NASDAQ:OPGN) Frequently Asked Questions

Is OpGen a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen or view top-rated stocks.

How has OpGen's stock been impacted by Coronavirus?

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPGN shares have decreased by 28.5% and is now trading at $1.48.
View which stocks have been most impacted by COVID-19.

Are investors shorting OpGen?

OpGen saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 949,000 shares, a decrease of 45.8% from the October 14th total of 1,750,000 shares. Based on an average trading volume of 2,670,000 shares, the short-interest ratio is presently 0.4 days.
View OpGen's Short Interest.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for OpGen.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, November, 11th. The medical research company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. OpGen had a negative trailing twelve-month return on equity of 81.57% and a negative net margin of 829.32%. During the same period in the previous year, the business posted ($0.40) EPS.
View OpGen's earnings history.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen shares reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What guidance has OpGen issued on next quarter's earnings?

OpGen updated its third quarter 2021 earnings guidance on Monday, November, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.20 million-$1.20 million, compared to the consensus revenue estimate of $1.72 million.

What price target have analysts set for OPGN?

3 equities research analysts have issued 12 month price targets for OpGen's stock. Their forecasts range from $4.00 to $7.00. On average, they expect OpGen's stock price to reach $5.50 in the next year. This suggests a possible upside of 271.6% from the stock's current price.
View analysts' price targets for OpGen or view top-rated stocks among Wall Street analysts.

Who are OpGen's key executives?

OpGen's management team includes the following people:

• Oliver Schacht, President, Chief Executive Officer & Director
• Johannes Bacher, Chief Operating Officer
• Vadim Sapiro, Chief Information Officer
• Faranak Atrzadeh, Chief Marketing & Scientific Affairs Officer
• Al Risdorfer, Senior Director-Human Resources

Who are some of OpGen's key competitors?

Some companies that are related to OpGen include Celcuity (CELC), Enzo Biochem (ENZ), Exagen (XGN), Centogene (CNTG), Biocept (BIOC), Vyant Bio (VYNT), Psychemedics (PMD), CannLabs (CANL), PharmChem (PCHM), AnPac Bio-Medical Science (ANPC), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), CBA Florida (CBAI), Zicix (ZICX) and First Choice Healthcare Solutions (FCHS).
View all of OPGN's competitors.

What other stocks do shareholders of OpGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did OpGen IPO?

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.92%), Marshall Wace LLP (0.67%), Renaissance Technologies LLC (0.40%), BlackRock Inc. (0.26%), Citadel Advisors LLC (0.15%) and Dimensional Fund Advisors LP (0.14%). Company insiders that own OpGen stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends for OpGen.

Which institutional investors are selling OpGen stock?

OPGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for OpGen or view top insider-selling stocks.

Which institutional investors are buying OpGen stock?

OPGN stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC, Bank of New York Mellon Corp, and Citadel Advisors LLC. Company insiders that have bought OpGen stock in the last two years include Johannes Bacher, and Oliver Schacht.
View insider buying and selling activity for OpGen or or view top insider-buying stocks.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $1.48.

How much money does OpGen make?

OpGen has a market capitalization of $57.65 million and generates $4.21 million in revenue each year. The medical research company earns $-26.21 million in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does OpGen have?

OpGen employs 102 workers across the globe.

What is OpGen's official website?

The official website for OpGen is www.opgen.com.

Where are OpGen's headquarters?

OpGen is headquartered at 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (240) 813-1260, via email at [email protected], or via fax at 301-869-9684.